34.19
-1.16 (-3.28%)
| Penutupan Terdahulu | 35.35 |
| Buka | 35.39 |
| Jumlah Dagangan | 386,480 |
| Purata Dagangan (3B) | 800,312 |
| Modal Pasaran | 1,949,862,400 |
| Harga / Pendapatan (P/E TTM) | 2.93 |
| Harga / Jualan (P/S) | 102.02 |
| Harga / Buku (P/B) | 2.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Feb 2025 - 17 Feb 2025 |
| Margin Keuntungan | 2,051.38% |
| Margin Operasi (TTM) | -1,146.93% |
| EPS Cair (TTM) | 11.66 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 21.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.74% |
| Nisbah Semasa (MRQ) | 8.99 |
| Aliran Tunai Operasi (OCF TTM) | -329.16 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -157.06 M |
| Pulangan Atas Aset (ROA TTM) | -18.17% |
| Pulangan Atas Ekuiti (ROE TTM) | 53.65% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Agios Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.20 |
|
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.51% |
| % Dimiliki oleh Institusi | 106.85% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Farallon Capital Management Llc | 30 Sep 2024 | 5,660,866 |
| Armistice Capital, Llc | 30 Sep 2024 | 2,207,070 |
| Erste Asset Management Gmbh | 30 Sep 2024 | 2,184,900 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 75.00 (Scotiabank, 119.36%) | Beli |
| Median | 56.50 (65.25%) | |
| Rendah | 51.00 (Raymond James, 49.17%) | Beli |
| Purata | 59.75 (74.76%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 45.52 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 10 Dec 2024 | 57.00 (66.72%) | Beli | 46.02 |
| 01 Nov 2024 | 55.00 (60.87%) | Beli | 44.87 | |
| Scotiabank | 09 Dec 2024 | 75.00 (119.36%) | Beli | 48.64 |
| 01 Nov 2024 | 53.00 (55.02%) | Beli | 44.87 | |
| Raymond James | 10 Oct 2024 | 51.00 (49.17%) | Beli | 41.82 |
| Leerink Partners | 27 Sep 2024 | 56.00 (63.79%) | Pegang | 45.61 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Dec 2024 | Pengumuman | European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease |
| 08 Dec 2024 | Pengumuman | Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat |
| 05 Nov 2024 | Pengumuman | Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition |
| 31 Oct 2024 | Pengumuman | Agios Reports Business Highlights and Third Quarter 2024 Financial Results |
| 23 Oct 2024 | Pengumuman | Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease |
| 17 Oct 2024 | Pengumuman | Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |